Skip to content
Screener

ArriVent BioPharma, Inc. AVBP Q3 2025 earnings

Reported November 10, 2025 · Before market open

EPS-$0.83Miss by $0.05
EPS estimate-$0.78

Next report

Nov 16, 2026 (in 2 months)
Revenue estimate$800.0K
EPS estimate-$1.07

Financials

Q3 2025

Income statement

See full
Operating income-$38.3M-58.1%
Net income-$35.0M-70.1%
EPS (diluted)-$0.83-36.1%

Balance sheet

See full
Cash & equivalents$112.7M-60.2%
Total debt$56.0K-73.7%
Total equity$305.0M+9.9%
Total assets$326.6M+11.6%

Cash flow

See full
Operating cash flow-$35.8M-119%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$748.5M-4.9%
Enterprise value$635.88M+26.0%

Returns & leverage

See full
Return on equity-52%—
Debt / equity0×0.0×
Current ratio14.9×-4.4×

FAQ

When did ArriVent BioPharma, Inc. report Q3 2025 earnings?
ArriVent BioPharma, Inc. (AVBP) reported Q3 2025 earnings on November 10, 2025 before market open.
What were ArriVent BioPharma, Inc.'s Q3 2025 revenue and EPS?
ArriVent BioPharma, Inc. reported eps of $-0.83 for Q3 2025.
Did ArriVent BioPharma, Inc. beat estimates in Q3 2025?
EPS missed the consensus estimate of $-0.78 by $0.05.
How did ArriVent BioPharma, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 36.1% from $-0.61.
Where can I find ArriVent BioPharma, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001104659-25-108839) and the 10-Q periodic report (0001104659-25-108847) directly on SEC EDGAR. The filing index links above go to sec.gov.